CD38 and non-small cell lung carcinoma: Importantly, a phase II clinical trial in NSCLC using daratumumab, a monoclonal antibody that targets CD38, showed no improved efficacy in patients who received daratumumab and anti–PD-L1 compared with anti–PD-L1 monotherapy (78).